COMy 2022 | What to look forward to at COMy 2022: clinical trial updates and more
In this video, Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, shares some insights into the 2022 COMy congress, which gives researchers and experts the chance to collaborate and share ideas to optimize myeloma treatment. Dr Mohty also mentions some of the interesting sessions that will be held at this year’s congress, as well as updates that will be discussed from various Phase III trials including the MUK Nine b, GRIFFIN, and GMMG-CONCEPT (NCT03188172, NCT02874742, NCT03104842) trials.
Transcript (edited for clarity)
COMy is about collaboration, is about putting together everybody to interact, to share ideas. And of course, to refine, to optimize the best treatment to our patient. This is why in this COMy 2022 meeting, we will have sessions that will be delivered by the IFM, the Intergroupe Francophone du Myélome, but also we’ll have another session delivered by the International Myeloma Society, because this is really important for collaboration...
COMy is about collaboration, is about putting together everybody to interact, to share ideas. And of course, to refine, to optimize the best treatment to our patient. This is why in this COMy 2022 meeting, we will have sessions that will be delivered by the IFM, the Intergroupe Francophone du Myélome, but also we’ll have another session delivered by the International Myeloma Society, because this is really important for collaboration.
I will not give you the details. We’ll have a few sessions about, “How do I manage some specific situations?” Very practical tips. Of course, don’t miss, please, the update about the most important and major recent Phase III trials in the field of multiple myeloma, the MUK Nine, the M-U-K nine. The CONCEPT, the GRIFFIN, the FORTE, the MASTER, all of them. You will hear some recent updates, so please join us during COMy.
Read more...
